(Reuters) -The U.S. Food and Drug Administration has approved updated COVID-19 vaccines made by Pfizer (NYSE:) and Moderna (NASDAQ:) targeting newer variants of the disease in time for a fall vaccination campaign, the agency said on Thursday.

The U.S. health regulator has approved the vaccines to target a variant known as “KP.2”, which dominated infections in recent months. It had asked manufacturers in June to target the strain.

“Vaccination continues to be the cornerstone of COVID-19 prevention,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

The FDA granted emergency use authorization for Moderna’s shot, branded as Spikevax, and Pfizer and BioNTech (NASDAQ:) shot branded as Comirnaty.